Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antitumor drug combination and preparation and application thereof

An anti-tumor and drug technology, which is applied in the field of combined anti-tumor drugs, can solve problems that cannot be explained well and the treatment effect of glioma is not satisfactory, and achieve good clinical application prospects, improve anti-cancer effect, EFFECTS OF IMPORTANT CLINICAL APPLICATIONS

Inactive Publication Date: 2018-09-11
WUHAN MAIDESEN MEDICAL TECH
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, anti-tumor angiogenesis therapy has excellent results in clinical studies of other tumors, but the effect in glioma treatment is not satisfactory; including bevacizumab to block VEGF, cilengitide to inhibit integrins, suni Imatinib or cediranib inhibit VEGF receptors, imatinib or dasatinib inhibit PDGFR, Enzastaurin inhibits protein kinase C and rapamycin, everolimus, or temsirolimus The company inhibits mTOR, and this phenomenon cannot be well explained at present

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antitumor drug combination and preparation and application thereof
  • Antitumor drug combination and preparation and application thereof
  • Antitumor drug combination and preparation and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] A combined drug for anti-tumor, the combined drug includes tumor angiogenesis inhibitor compounds and disulfiram, the weight ratio of the tumor angiogenesis inhibitor compounds and disulfiram is: (1-15) :(1-20), such as 1:1, 1:5, 1:7.5, 1:10, 1:15, 1:20, 5:1, 10:1 or 15:1, etc.; preferred 1:( 4-10).

[0021] The tumor angiogenesis inhibitor compounds include but not limited to sunitinib, cediranib, sorafenib, tivozanib (tivozani), cilengitide, imatinib, dasatinib , Enzastaurin, rapamycin, everolimus and temsirolimus at least one.

[0022] As a further preferred embodiment, the combination drug further includes at least one pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier includes but is not limited to at least one of liposome, polymer nanoparticle and magnetic nanoparticle, and its dosage is 5 to 50 times, such as 10 times or 20 times, the weight of the combined drug.

[0023] The drug in this embodiment can effectively treat liver cancer,...

Embodiment 2

[0025] The preparation method of the combination drug for anti-tumor in Example 1 is as follows: mix the disulfiram powder and the tumor angiogenesis inhibitor compound powder uniformly in proportion.

[0026] The combined drug can be made into solid preparation or injection, but the active ingredients are consistent with those described in Example 1, including tumor angiogenesis inhibitor compounds and disulfiram, and carriers can also be added; solid preparations include tablets, capsules , pills, micropills, etc. For specific preparation methods, please refer to the preparation methods of corresponding dosage forms in the prior art.

Embodiment 3

[0028] Tumor angiogenesis inhibitor compounds and disulfiram at a ratio of 1:7 were used as the experimental group, and ordinary purified water was used as the comparison group.

[0029] Experimental objects: 10 healthy mice, 5 in each group, with an average body weight of 19±1g, and the tested animals passed the physical examination.

[0030] The comparison group was fed with purified water, and the combined drug in the experimental group was fed to the mice 3 times a day at 3 mL each time, and the mice were continuously observed for 10 days, their body weight was weighed, and their vitality was observed. The body weight and vigor of all the mice in the experiment did not change substantially, so the toxic and side effects of the combined drug in the present invention were small or not.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an antitumor drug combination and a preparation and application thereof. The drug combination comprises a tumor angiogenesis inhibitor compound and disulfiram. Weight ratio ofthe angiogenesis inhibitor compound to disulfiram is (1-15): (1-20). By combination of the tumor angiogenesis inhibitor compound and disulfiram for medication, the antitumor drug combination has thefunction of remarkably raising anticancer effect in comparison with any single ingredient. In addition, tumor inhibiting rate is raised by 20% and above. The data is a great progress in the research on cancer treatment. In the inventor's first research, it is found that the combination of the angiogenesis inhibitor and disulfiram at a specific ratio has a remarkable synergistic effect and the drugcombination has a good clinical application prospect.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a novel combination drug for anti-tumor and the application of the combination drug. Background technique [0002] Studies have shown that there are two mechanisms for the supply of blood vessels that tumor growth depends on: 1. The tumor can stimulate the adjacent normal blood vessels to generate branch blood vessels through the cytokines secreted by the tumor itself for its own supply; Produces a vascular-like result, which is then "grafted" on top of adjacent normal blood vessels. The mechanisms of the two are essentially different. Simply put, the sequence of the formation of internal and external blood vessels is different. The similar part of the two is that they both need to produce blood vessel-like structures. This DIY feature is the main reason why anti-angiogenic drugs can work. [0003] Although anti-cell proliferation drugs can kill tumor cells, the remaining tumo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/145A61P35/00
Inventor 刘明星王瑜吴建宏
Owner WUHAN MAIDESEN MEDICAL TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com